BR0007919A - Composição purina 2,6,9-trisubstituìda - Google Patents

Composição purina 2,6,9-trisubstituìda

Info

Publication number
BR0007919A
BR0007919A BR0007919-7A BR0007919A BR0007919A BR 0007919 A BR0007919 A BR 0007919A BR 0007919 A BR0007919 A BR 0007919A BR 0007919 A BR0007919 A BR 0007919A
Authority
BR
Brazil
Prior art keywords
purine composition
trisubstituted purine
composition
trisubstituted
trisubstitued
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
BR0007919-7A
Other languages
English (en)
Inventor
Robert T Lum
Steven R Schow
Cheri Lynn Blum
Richard Mackman
Michael M Wick
Jeffrey A Zablocki
Prabha Ibrahim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Palo Alto Inc
Original Assignee
Gilead Palo Alto Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Palo Alto Inc filed Critical Gilead Palo Alto Inc
Publication of BR0007919A publication Critical patent/BR0007919A/pt
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6

Abstract

"COMPOSIçãO PURINA 2,6,9-TRISUBSTITUìDA". Composição purina 2,6,9-trisubstituída que é útil para inibir desordens proliferativas celulares e como um agente antifúngico.
BR0007919-7A 1999-02-01 2000-01-20 Composição purina 2,6,9-trisubstituìda Pending BR0007919A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24122499A 1999-02-01 1999-02-01
PCT/US2000/001407 WO2000044750A1 (en) 1999-02-01 2000-01-20 PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND Iλ-A$g(a)

Publications (1)

Publication Number Publication Date
BR0007919A true BR0007919A (pt) 2002-04-09

Family

ID=22909777

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0007919-7A Pending BR0007919A (pt) 1999-02-01 2000-01-20 Composição purina 2,6,9-trisubstituìda

Country Status (26)

Country Link
EP (1) EP1150982B1 (pt)
JP (1) JP3681984B2 (pt)
KR (1) KR20010093308A (pt)
CN (1) CN1353713A (pt)
AR (1) AR029612A1 (pt)
AT (1) ATE306487T1 (pt)
AU (1) AU2969300A (pt)
BR (1) BR0007919A (pt)
CA (1) CA2361518A1 (pt)
CZ (1) CZ20012765A3 (pt)
DE (1) DE60023268T2 (pt)
DK (1) DK1150982T3 (pt)
ES (1) ES2246829T3 (pt)
GE (1) GEP20033092B (pt)
HK (1) HK1044334A1 (pt)
HU (1) HUP0200535A3 (pt)
IL (2) IL144675A0 (pt)
MX (1) MXPA01007851A (pt)
NO (1) NO327776B1 (pt)
NZ (1) NZ513371A (pt)
PL (1) PL350001A1 (pt)
RU (1) RU2001124352A (pt)
TR (1) TR200102714T2 (pt)
TW (1) TW538044B (pt)
UA (1) UA74142C2 (pt)
WO (1) WO2000044750A1 (pt)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6413974B1 (en) 1998-02-26 2002-07-02 Aventis Pharmaceuticals Inc. 6,9,-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines
US6479487B1 (en) 1998-02-26 2002-11-12 Aventis Pharmaceuticals Inc. 6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines
WO2000012485A1 (en) 1998-08-29 2000-03-09 Astrazeneca Ab Pyrimidine compounds
ES2270612T3 (es) 1998-08-29 2007-04-01 Astrazeneca Ab Compuestos de pirimidina.
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
GB9907658D0 (en) 1999-04-06 1999-05-26 Zeneca Ltd Chemical compounds
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
JP2003531111A (ja) 1999-12-17 2003-10-21 アライアッド・ファーマシューティカルズ・インコーポレーテッド プロトンポンプインヒビター
GB0004888D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004886D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0007371D0 (en) 2000-03-28 2000-05-17 Astrazeneca Uk Ltd Chemical compounds
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
US6861524B2 (en) 2000-10-31 2005-03-01 Aventis Pharmaceuticals Inc. Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
GB0113041D0 (en) 2001-05-30 2001-07-18 Astrazeneca Ab Chemical compounds
GB2378180B8 (en) 2001-06-27 2009-10-21 Cyclacel Ltd New purine derivatives
AU2002343604C1 (en) 2001-10-30 2009-09-17 Conforma Therapeutics Corporation Purine analogs having HSP90-inhibiting activity
US20050154046A1 (en) * 2004-01-12 2005-07-14 Longgui Wang Methods of treating an inflammatory-related disease
AU2002357295A1 (en) 2001-12-18 2003-06-30 Cv Therapeutics, Inc. A2a adenosine receptor antagonists
DK1492581T3 (da) 2002-02-15 2007-04-30 Cv Therapeutics Inc Polymerbelægning til medicinske anordninger
JP2005524672A (ja) 2002-03-09 2005-08-18 アストラゼネカ アクチボラグ Ｃｄｋ阻害活性を有するイミダゾリル置換ピリミジン誘導体
GB0205693D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
GB0205688D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
GB0205690D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
GB0219054D0 (en) 2002-08-15 2002-09-25 Cyclacel Ltd New purine derivatives
GB0219052D0 (en) * 2002-08-15 2002-09-25 Cyclacel Ltd New puring derivatives
FR2851248B1 (fr) * 2003-02-18 2005-04-08 Aventis Pharma Sa Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation
US7476670B2 (en) 2003-02-18 2009-01-13 Aventis Pharma S.A. Purine derivatives, method for preparing, pharmaceutical compositions and novel use
GB0311276D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
GB0311274D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
WO2005028434A2 (en) 2003-09-18 2005-03-31 Conforma Therapeutics Corporation Novel heterocyclic compounds as hsp90-inhibitors
TW200528101A (en) 2004-02-03 2005-09-01 Astrazeneca Ab Chemical compounds
GB0407723D0 (en) * 2004-04-05 2004-05-12 Novartis Ag Organic compounds
EP1674467A1 (en) * 2004-12-22 2006-06-28 4Sc Ag 2,5- and 2,6-disubstituted benzazole derivatives useful as protein kinase inhibitors
FR2880626B1 (fr) * 2005-01-13 2008-04-18 Aventis Pharma Sa Derives de la purine, compositions les contenant et utilisation
US7544672B2 (en) 2005-03-30 2009-06-09 Conforma Therapeutics Corporation Alkynyl pyrrolo[2,3-d]pyrimidines and related analogs as HSP90-inhibitors
US8080555B2 (en) * 2005-05-16 2011-12-20 Prometic Biosciences Inc. Purine derivatives and their use for treatment of autoimmune diseases
JP4992716B2 (ja) * 2005-08-12 2012-08-08 アステラス製薬株式会社 薬剤の標的蛋白質を同定する方法及び標的蛋白質を用いた糖尿病治療薬のスクリーニング方法
CA2623374A1 (en) 2005-09-30 2007-04-05 Astrazeneca Ab Imidazo [1,2-a] pyridine having anti-cell-proliferation activity
GB0706632D0 (en) 2007-04-04 2007-05-16 Cyclacel Ltd New purine derivatives
PE20100362A1 (es) * 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
CZ302122B6 (cs) * 2009-01-28 2010-10-20 Univerzita Palackého v Olomouci Substituované deriváty 6-(2-aminobenzylamino)purinu, jejich použití jako léciva a prípravky tyto slouceniny obsahující
AR077280A1 (es) 2009-06-29 2011-08-17 Incyte Corp Pirimidinonas como inhibidores de pi3k, y composiciones farmaceuticas que los comprenden
US8759359B2 (en) 2009-12-18 2014-06-24 Incyte Corporation Substituted heteroaryl fused derivatives as PI3K inhibitors
WO2011130342A1 (en) 2010-04-14 2011-10-20 Incyte Corporation FUSED DERIVATIVES AS ΡI3Κδ INHIBITORS
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
ES2764848T3 (es) 2010-12-20 2020-06-04 Incyte Holdings Corp N-(1-(fenilo sustituido)etilo)-9H-purina-6-aminas como inhibidores de PI3K
WO2012125629A1 (en) 2011-03-14 2012-09-20 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
US9126948B2 (en) 2011-03-25 2015-09-08 Incyte Holdings Corporation Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
PE20181272A1 (es) 2011-09-02 2018-08-03 Incyte Holdings Corp Heterociclilaminas como inhibidores de pi3k
AU2012311184A1 (en) 2011-09-22 2014-03-06 Pfizer Inc. Pyrrolopyrimidine and purine derivatives
WO2013130461A1 (en) 2012-02-29 2013-09-06 The Scripps Research Institute Wee1 degradation inhibitors
EP2634190A1 (en) * 2012-03-01 2013-09-04 Lead Discovery Center GmbH Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhinitors
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
CZ306894B6 (cs) * 2013-02-08 2017-08-30 Univerzita PalackĂ©ho v Olomouci 2-Substituované-6-biarylmethylamino-9-cyklopentyl-9H-purinové deriváty, jejich použití jako léčiva a farmaceutické přípravky tyto sloučeniny obsahující
WO2014134750A1 (zh) * 2013-03-08 2014-09-12 中国人民解放军军事医学科学院放射与辐射医学研究所 2,6,9-三取代嘌呤衍生物及其制备方法与应用
JPWO2015005491A1 (ja) * 2013-07-12 2017-03-02 国立大学法人京都大学 疾病の発症又は進行の一因となる異常スプライシングを抑制できる物質のスクリーニング方法
FR3011240A1 (fr) 2013-10-01 2015-04-03 Centre Nat Rech Scient Inhibiteurs de 5'-nucleotidases et leurs utilisations therapeutiques
US10077277B2 (en) 2014-06-11 2018-09-18 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
CR20210055A (es) 2015-02-27 2021-04-27 Incyte Corp SALES DE IHNIBIDOR DE PI3K Y PROCESOS DE PREPARACIÓN (Divisional 2017-0389)
WO2016183060A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
US9988401B2 (en) 2015-05-11 2018-06-05 Incyte Corporation Crystalline forms of a PI3K inhibitor
CN107235981B (zh) * 2017-05-25 2019-10-25 北京工业大学 低氧激活o6-苄基-2-硝基嘌呤衍生物及制法和应用
CN107903274A (zh) * 2017-12-28 2018-04-13 窦玉玲 一种胺类化合物及其在抗肿瘤药物中的应用
CN110256436B (zh) * 2019-06-27 2020-06-09 南京雷正医药科技有限公司 作为Trk激酶抑制剂的嘌呤类化合物
CN117479944A (zh) * 2021-04-02 2024-01-30 泰州亿腾景昂药业股份有限公司 周期蛋白依赖性激酶抑制剂
WO2023046128A1 (en) * 2021-09-27 2023-03-30 Taizhou Eoc Pharma Co., Ltd. A cyclin-dependent kinase inhibitor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2741881B1 (fr) * 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
US5866702A (en) * 1996-08-02 1999-02-02 Cv Therapeutics, Incorporation Purine inhibitors of cyclin dependent kinase 2
CA2297967A1 (en) * 1997-08-07 1999-02-18 The Regents Of The University Of California Purine inhibitor of protein kinases, g proteins and polymerases

Also Published As

Publication number Publication date
DE60023268D1 (de) 2006-03-02
CN1353713A (zh) 2002-06-12
HUP0200535A3 (en) 2002-11-28
DE60023268T2 (de) 2006-06-01
UA74142C2 (uk) 2005-11-15
NO20013751L (no) 2001-09-27
JP2002535405A (ja) 2002-10-22
HK1044334A1 (zh) 2002-10-18
AU2969300A (en) 2000-08-18
KR20010093308A (ko) 2001-10-27
IL144675A (en) 2008-11-26
DK1150982T3 (da) 2005-12-27
TW538044B (en) 2003-06-21
ATE306487T1 (de) 2005-10-15
ES2246829T3 (es) 2006-03-01
NO327776B1 (no) 2009-09-21
MXPA01007851A (es) 2003-06-04
GEP20033092B (en) 2003-10-27
NO20013751D0 (no) 2001-07-31
RU2001124352A (ru) 2004-02-20
EP1150982A1 (en) 2001-11-07
IL144675A0 (en) 2002-05-23
EP1150982B1 (en) 2005-10-12
PL350001A1 (en) 2002-10-21
HUP0200535A2 (hu) 2002-07-29
AR029612A1 (es) 2003-07-10
NZ513371A (en) 2003-08-29
WO2000044750A1 (en) 2000-08-03
CA2361518A1 (en) 2000-08-03
TR200102714T2 (tr) 2002-01-21
JP3681984B2 (ja) 2005-08-10
CZ20012765A3 (cs) 2002-08-14

Similar Documents

Publication Publication Date Title
BR0007919A (pt) Composição purina 2,6,9-trisubstituìda
BR9710801A (pt) Inibidores de purina de cinase 2 dependente deciclina e ikb-a
BR0107869A (pt) Composições farmacêuticas eletrogiradas
ES2176795T3 (es) Composiciones a base de esfingomielanasa y su utilizacion.
MXPA02007822A (es) Composicion cosmetica, especialmente para el uso en piel envejecida y/o tensa.
AR019503A1 (es) Utilizacion de derivados sustituidos en 3 del estilbeno como agentes activos desodorantes en las composiciones cosmeticas
BR9804106A (pt) Mecanismo de engrenagem diferencial e conjunto de caixa para uso com mecanismo diferencial.
MEP35308A (en) COMPOUNDS SPECIFIC TO ADENOSINE A1, A2a, AND A3 RECEPTOR AND USES THEREOF
ES2109895T1 (es) Producto y procedimiento para el teñido oxidativo de fibras de queratina.
BRPI0006551B8 (pt) composição pronta para uso na tintura de oxidação das fibras queratínicas, processos de tintura das fibras queratínicas e dispositivo com vários compartimentos ou “kit” para a tintura de oxidação das fibras queratínicas.
BR9711377B1 (pt) processo para adaptação de uma interface aérea de um sistema de rádio privado para que a mesma seja compatìvel com uma interface aérea de uma rede móvel, sistema para uso em possibilitar a um usuário de uma rede de comunicações móveis comunicar-se com um sistema de rádio privado, e sistema de rádio privado.
HN1998000143A (es) Tetrahidronaftalenos substituidos y compuestos analogos.
BR0110751A (pt) Dispositivo
BR0007864A (pt) Composto, e, uso de um composto
BR0011850A (pt) Agonistas de receptor a2a de propargil fenil éter
AR004089A1 (es) Utilizacion de un antagonista de substancia p en una composicion topica , como agente antitranspirante.
DE50004443D1 (de) Wirkstoffhaltige komposition sowie deren herstellung und verwendung
BR0111630A (pt) Espiral para inseto
BR0214706A (pt) Estrutura absorvente envolta
AR015945A1 (es) Composiciones de spray para el cabello autofobicas
HUP9701611A2 (hu) Nagy elektrolittartalmú V/O emulzió, alkalmazása bőrkozmetikai készítményekben, különösen irritáció és/vagy érzékeny bőr kezelésére
BR0116152B1 (pt) aditivo adequado para uso como emulsificador e solubilizador, uso de um aditivo, e, composição.
AR029092A1 (es) Composiciones para el tratamiento del cabello
BR9807691A (pt) Composição aerossol antiperspirante, e , uso de pentano como um agente de resfriamento da pele
BR9900821A (pt) Processo para melhorar a aparência de uma composição de polimento de piso, composição de veìculo para polimento de pisos, e, uso de ìon cobre divalente.

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8, 10(VIII), 11, 13, 24 E 25 DA LPI

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.